{"id":304514,"date":"2026-10-13T10:47:07","date_gmt":"2026-10-13T05:17:07","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=304514"},"modified":"2026-10-13T10:47:07","modified_gmt":"2026-10-13T05:17:07","slug":"chronic-therapy-enzyme-and-pharmacy-retail-stocks-forward-view-shortlist","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/chronic-therapy-enzyme-and-pharmacy-retail-stocks-forward-view-shortlist\/","title":{"rendered":"3 Chronic Therapy, Enzyme and Pharmacy Retail Stocks With a Strong Future Roadmap: Mankind Pharma, Advanced Enzyme Technologies and Medplus Health Services"},"content":{"rendered":"

Mankind Pharma Rs 2,400.00, P\/E 47.91. Advanced Enzyme Rs 266.70, P\/E 17.28. Medplus Rs 627.60, P\/E 36.06. Closing prices of 12 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Chronic therapy, enzyme and pharmacy retail stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, Advanced Enzyme in enzymes and probiotics for food, nutrition and pharma and Medplus in a pharmacy retail chain across several states. FY26 revenue growth was 14.8% at Mankind Pharma, 16.5% at Advanced Enzyme and 12.6% at Medplus. P\/E stands at 47.91 for Mankind Pharma (industry 37.59), 17.28 for Advanced Enzyme (industry 37.59) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Chronic therapy, enzyme and pharmacy retail stocks give investors exposure to medicines, nutrition ingredients and pharmacy stores that patients rely on. Prescription growth, store additions and margins decide how much of that demand turns into profit.<\/p>\n

This list covers three chronic therapy, enzyme and pharmacy retail stocks: Mankind Pharma for branded formulations across chronic and acute therapies, Advanced Enzyme Technologies for enzymes and probiotics for food, nutrition and pharma and Medplus Health Services for a pharmacy retail chain across several states. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n